How mitochondria affect response to antibody–drug therapies in advanced lung cancer
Investigating mitochondrial networks as a critical determinant of response to antibody drug conjugates in advanced NSCLC
This project looks at whether differences in tumor mitochondria help explain why some people with advanced non-small cell lung cancer respond better to new antibody–drug conjugate therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11301846 on NIH RePORTER |
What this research studies
From your perspective, researchers will study tumors from people with advanced or metastatic non-small cell lung cancer to see how the structure and behavior of mitochondria relate to response to ADCs that carry the DXd payload (such as T‑DXd, HER3‑DXd, and Dato‑DXd). They will analyze tumor tissue with lab tests like IHC and molecular assays to measure mitochondrial networks and proteins that control apoptosis. Those laboratory findings will be compared with clinical outcomes after ADC treatment to look for patterns linked to benefit or resistance. The goal is to find biological features that could one day help doctors choose or combine therapies more effectively.
Who could benefit from this research
Good fit: Ideal candidates are people with advanced or metastatic non-small cell lung cancer who are being considered for or have received DXd-containing antibody–drug conjugates and who have available tumor tissue for analysis.
Not a fit: People with early-stage lung cancer, non-NSCLC tumor types, or those without available tumor samples are unlikely to be eligible or directly benefit from this research.
Why it matters
Potential benefit: If successful, this work could help predict which patients with advanced NSCLC are most likely to benefit from DXd-containing ADC therapies and guide treatment decisions.
How similar studies have performed: DXd-containing ADCs have shown activity in advanced NSCLC after standard therapies, but using mitochondrial network features to predict response is a new and largely untested approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Lisberg, Aaron Elliott — University of California Los Angeles
- Study coordinator: Lisberg, Aaron Elliott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.